- As part of the deal, Accord will utilize more than 100 sales, medical, and marketing professionals to drive the adoption of Anktiva in the U.K., the European Union, Norway, Iceland, and Liechtenstein.
- ImmunityBio founder Patrick Soon-Shiong said the company’s goal is to expand access to Anktiva by completing a randomized trial in patients with BCG-naïve disease.
- The company announced on Wednesday that it has received EU approval for the use of Anktiva in combination with BCG.
ImmunityBio Inc. (IBRX) on Thursday announced a partnership with Accord Healthcare to expand access to Anktiva across 30 countries.
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.
ImmunityBio shares were down around 9% in Thursday’s opening trade after surging about 42% on Wednesday. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.
ImmunityBio’s Partnership With Accord
ImmunityBio said its partnership with Accord will help it unlock the full commercial potential of Anktiva in Europe.
“Our partnership with Accord marks a significant step in our European growth strategy and our mission to redefine cancer care,” said ImmunityBio CEO Richard Adcock.
As part of the deal, Accord will utilize more than 100 sales, medical, and marketing professionals to drive the adoption of Anktiva in the United Kingdom, the European Union, Norway, Iceland, and Liechtenstein.
ImmunityBio founder Patrick Soon-Shiong said that the company’s goal is to broaden access to Anktiva by completing the randomized trial in patients with BCG-naïve disease, which refers to non-muscle invasive bladder cancer (NMIBC) in patients who have never received Bacillus Calmette-Guérin (BCG) immunotherapy, or those who experience recurrence more than 24 months after completing prior BCG treatment.
ImmunityBio Receives EU Approval
ImmunityBio announced on Wednesday that it has received EU approval for the use of Anktiva in combination with BCG.
This comes days after the Saudi Food and Drug Authority (SFDA) encouraged the company to submit a regulatory filing for its recombinant BCG therapy to help address treatment shortages and expand access.
The company also said that it is in talks with Saudi regulators to broaden Anktiva’s use in combination with checkpoint inhibitors across multiple tumor types. Last month, the SFDA granted ImmunityBio accelerated approval for Anktiva in the treatment of metastatic non-small cell lung cancer and for BCG-unresponsive bladder cancer.
IBRX stock is up 306% year-to-date and 106% over the past 12 months.
Also See: Jobless Claims Drop By Most In Over Two Months, Coming In Below Expectations
For updates and corrections, email newsroom[at]stocktwits[dot]com.